Market Overview

CVS Is Transforming Health Care, Piper Sandler Says In Upgrade

CVS Is Transforming Health Care, Piper Sandler Says In Upgrade

Piper Sandler analyst Sarah E. James initiates coverage on CVS Health Corp (NYSE: CVS) with an Overweight rating and a $72 price target.

The CVS Takeaways: “CVS is well positioned to transform health care access,” James wrote in a note. The company’s large footprint, growth in Medicaid, and new programs are among the reasons she initiated a bullish rating.

Seventy percent of the U.S. population lives within three minutes of a CVS store. James believes the company’s expansion of its HealthHubs are helping drive customers to stores and improve margins.

“See potential for best in class diversified healthcare delivery model with long term margin expansion. We believe leveraging pharmacy expertise and integrating retail/HealthHubs create attractive, local care delivery,” James said. “We believe CVS’ commitment to innovative tech and the Aetna integrations will drive the company’s long term growth beyond the legacy depiction of a retail pharmacy/PBM into a transformative healthcare company."

Gaining Customer with COVID-19 Tests: CVS Health has performed over 3 million COVID-19 tests. The company has the capacity to complete 1.5 million per month. James notes that 40% of those tested were not current CVS pharmacy customers.

“We believe the pandemic provides CVS with the opportunity to extend/accelerate its digital engagement strategy to customers and non-customers alike,” James said.

The 1,940 CVS locations that offer testing are significantly higher than rivals Rite Aid Corporation (NYSE: RAD) with 258 locations and Walgreens Boots Alliance Inc (NASDAQ: WBA) with 124 locations.

Boost From Joe Biden Win: James is forecasting a Joe Biden presidential win could fuel Medicaid expansion, which would benefit CVS. James estimates $700 million in revenue growth from a Biden win. The note estimates $8.4 billion in Medicaid related revenue for CVS in the current fiscal year.

Price Action: Shares of CVS Health were modestly higher at $57.90. Shares have traded between $52.04 and $77.03 over the last 52 weeks and are down 23% in 2020.

Latest Ratings for CVS

Sep 2020Piper SandlerInitiates Coverage OnOverweight
Aug 2020Credit SuisseMaintainsOutperform
Aug 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings


Related Articles (CVS)

View Comments and Join the Discussion!

Posted-In: Covid-19 Joe Biden Medicaid Piper SandlerAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga

Latest Ratings

NOMDBTIGInitiates Coverage On30.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at